{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:10:20Z","timestamp":1793394620884,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,9,15]],"date-time":"2010-09-15T00:00:00Z","timestamp":1284508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s11906-010-0146-y","type":"journal-article","created":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T21:02:25Z","timestamp":1284411745000},"page":"404-410","source":"Crossref","is-referenced-by-count":162,"title":["Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage"],"prefix":"10.1007","volume":"12","author":[{"given":"Carrie Anna","family":"Geisberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,15]]},"reference":[{"key":"146_CR1","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1542\/peds.2007-0575","volume":"121","author":"SM Shankar","year":"2008","unstructured":"Shankar SM, Marina N, Hudson MM, et al.: Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children\u2019s Oncology Group. Pediatrics 2008, 121:e387\u2013e396.","journal-title":"Pediatrics"},{"key":"146_CR2","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","volume":"266","author":"LJ Steinherz","year":"1991","unstructured":"Steinherz LJ, Steinherz PG, Tan CT, et al.: Cardiac toxicity 4 to 20\u00a0years after completing anthracycline therapy. JAMA 1991, 266:1672\u20131677.","journal-title":"JAMA"},{"key":"146_CR3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"\u2022 Cardinale D, Colombo A, Lamantia G, et al.: Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010, 55:213\u2013220. In a prospective clinical trial, 201 patients with AIC were treated with enalapril and carvedilol promptly after diagnosis of LV ejection fraction of 45% or less. Complete recovery of the ejection fraction occurred in 85 patients (42%). The percentage of responders decreased when the time from chemotherapy to diagnosis of reduced ejection fraction was greater than 4\u00a0months.","journal-title":"J Am Coll Cardiol"},{"key":"146_CR4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/hrt.2007.136093","volume":"94","author":"SE Lipshultz","year":"2008","unstructured":"\u2022 Lipshultz SE, Alvarez JA, Scully RE: Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008, 94:525\u2013533. A review of results from the Childhood Cancer Survivor Study (CCSS) discussing increased cumulative incidence of chronic health conditions\u00a030\u00a0years after treatment. The review highlights proposed pathophysiology that occurs during late-onset cardiotoxicity after childhood exposure and recommendations for monitoring and treatment.","journal-title":"Heart"},{"key":"146_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-125-1-199607010-00008","volume":"125","author":"K Shan","year":"1996","unstructured":"Shan K, Lincoff AM, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 1996, 125:47\u201358.","journal-title":"Ann Intern Med"},{"key":"146_CR6","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE, et al.: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231\u20131238.","journal-title":"J Clin Oncol"},{"key":"146_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/mi.5.3.6","volume":"5","author":"X Peng","year":"2005","unstructured":"Peng X, Chen B, Lim CC, Sawyer DB: The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 2005, 5:163\u2013171.","journal-title":"Mol Interv"},{"key":"146_CR8","first-page":"1093","volume":"65","author":"DV Unverferth","year":"1981","unstructured":"Unverferth DV, Magorien RD, Unverferth BP, et al.: Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep 1981, 65:1093\u20131097.","journal-title":"Cancer Treat Rep"},{"key":"146_CR9","first-page":"4592","volume":"62","author":"AC Childs","year":"2002","unstructured":"Childs AC, Phaneuf SL, Dirks AJ, et al.: Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002, 62:4592\u20134598.","journal-title":"Cancer Res"},{"key":"146_CR10","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1161\/01.CIR.96.8.2641","volume":"96","author":"SE Lipshultz","year":"1997","unstructured":"Lipshultz SE, Rifai N, Sallan SE, et al.: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96:2641\u20132648.","journal-title":"Circulation"},{"key":"146_CR11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/mgme.2000.3043","volume":"71","author":"MS Horenstein","year":"2000","unstructured":"Horenstein MS, Vander Heide RS, L\u2019Ecuyer TJ: Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 2000, 71:436\u2013444.","journal-title":"Mol Genet Metab"},{"key":"146_CR12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.yjmcc.2006.06.009","volume":"41","author":"M Tokarska-Schlattner","year":"2006","unstructured":"Tokarska-Schlattner M, Zaugg M, Zuppinger C, et al.: New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006, 41:389\u2013405.","journal-title":"J Mol Cell Cardiol"},{"key":"146_CR13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.RES.84.3.257","volume":"84","author":"DB Sawyer","year":"1999","unstructured":"Sawyer DB, Fukazawa R, Arstall MA, Kelly RA: Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999, 84:257\u2013265.","journal-title":"Circ Res"},{"key":"146_CR14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI118909","volume":"98","author":"HC Yen","year":"1996","unstructured":"Yen HC, Oberley TD, Vichitbandha S, et al.: The protective role of manganese superoxide dismutase against Adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996, 98:1253\u20131260.","journal-title":"J Clin Invest"},{"key":"146_CR15","doi-asserted-by":"crossref","first-page":"9182","DOI":"10.1016\/S0021-9258(17)47282-6","volume":"259","author":"KM Tewey","year":"1984","unstructured":"Tewey KM, Chen GL, Nelson EM, Liu LF: Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984, 259:9182\u20139187.","journal-title":"J Biol Chem"},{"key":"146_CR16","doi-asserted-by":"crossref","first-page":"H1956","DOI":"10.1152\/ajpheart.00407.2008","volume":"295","author":"J Liu","year":"2008","unstructured":"Liu J, Mao W, Ding B, Liang CS: ERKs\/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 2008, 295:H1956\u2013H1965.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"146_CR17","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.yjmcc.2003.09.012","volume":"35","author":"R Fukazawa","year":"2003","unstructured":"Fukazawa R, Miller TA, Kuramochi Y, et al.: Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase\/Akt. J Mol Cell Cardiol 2003, 35:1473\u20131479.","journal-title":"J Mol Cell Cardiol"},{"key":"146_CR18","doi-asserted-by":"crossref","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","volume":"273","author":"YY Zhao","year":"1998","unstructured":"Zhao YY, Sawyer DR, Baliga RR, et al.: Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998, 273:10261\u201310269.","journal-title":"J Biol Chem"},{"key":"146_CR19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/01.CIR.100.4.407","volume":"100","author":"S Rohrbach","year":"1999","unstructured":"Rohrbach S, Yan X, Weinberg EO, et al.: Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation 1999, 100:407\u2013412.","journal-title":"Circulation"},{"key":"146_CR20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1124\/dmd.107.018895","volume":"36","author":"OS Bains","year":"2008","unstructured":"Bains OS, Takahashi RH, Pfeifer TA, et al.: Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin. Drug Metab Dispos 2008, 36:904\u2013910.","journal-title":"Drug Metab Dispos"},{"key":"146_CR21","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","volume":"112","author":"L Wojnowski","year":"2005","unstructured":"Wojnowski L, Kulle B, Schirmer M, et al.: NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005, 112:3754\u20133762.","journal-title":"Circulation"},{"key":"146_CR22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12012-007-0024-2","volume":"7","author":"S Deng","year":"2007","unstructured":"Deng S, Wojnowski L: Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007, 7:129\u2013134.","journal-title":"Cardiovasc Toxicol"},{"key":"146_CR23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/scdb.1998.0281","volume":"10","author":"F Charron","year":"1999","unstructured":"Charron F, Nemer M: GATA transcription factors and cardiac development. Semin Cell Dev Biol 1999, 10:85\u201391.","journal-title":"Semin Cell Dev Biol"},{"key":"146_CR24","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1128\/MCB.13.10.6290","volume":"13","author":"J O\u2019Prey","year":"1993","unstructured":"O\u2019Prey J, Ramsay S, Chambers I, Harrison PR: Transcriptional up-regulation of the mouse cytosolic glutathione peroxidase gene in erythroid cells is due to a tissue-specific 3\u2032 enhancer containing functionally important CACC\/GT motifs and binding sites for GATA and Ets transcription factors. Mol Cell Biol 1993, 13:6290\u20136303.","journal-title":"Mol Cell Biol"},{"key":"146_CR25","doi-asserted-by":"crossref","first-page":"22800","DOI":"10.1074\/jbc.272.36.22800","volume":"272","author":"R Jeyaseelan","year":"1997","unstructured":"Jeyaseelan R, Poizat C, Baker RK, et al.: A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J Biol Chem 1997, 272:22800\u201322808.","journal-title":"J Biol Chem"},{"key":"146_CR26","doi-asserted-by":"crossref","first-page":"H803","DOI":"10.1152\/ajpcell.1999.276.4.C803","volume":"276","author":"N Saadane","year":"1999","unstructured":"Saadane N, Alpert L, Chalifour LE: TAFII250, Egr-1, and D-type cyclin expression in mice and neonatal rat cardiomyocytes treated with doxorubicin. Am J Physiol 1999, 276:H803\u2013814.","journal-title":"Am J Physiol"},{"key":"146_CR27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.HYP.34.6.1223","volume":"34","author":"S Chen","year":"1999","unstructured":"Chen S, Garami M, Gardner DG: Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes. Hypertension 1999, 34:1223\u20131231.","journal-title":"Hypertension"},{"key":"146_CR28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10741-005-5251-7","volume":"10","author":"H Granzier","year":"2005","unstructured":"Granzier H, Wu Y, Siegfried L, LeWinter M: Titin: physiological function and role in cardiomyopathy and failure. Heart Fail Rev 2005, 10:211\u2013223.","journal-title":"Heart Fail Rev"},{"key":"146_CR29","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1074\/jbc.M308033200","volume":"279","author":"CC Lim","year":"2004","unstructured":"Lim CC, Zuppinger C, Guo X, et al.: Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 2004, 279:8290\u20138299.","journal-title":"J Biol Chem"},{"key":"146_CR30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.109.895771","volume":"121","author":"A Angelis De","year":"2010","unstructured":"De Angelis A, Piegari E, Cappetta D, et al.: Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010, 121:276\u2013292.","journal-title":"Circulation"},{"key":"146_CR31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/CIRCULATIONAHA.109.902221","volume":"121","author":"C Huang","year":"2010","unstructured":"Huang C, Zhang X, Ramil JM, et al.: Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 2010, 121:675\u2013683.","journal-title":"Circulation"},{"key":"146_CR32","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2002.20.6.1677","volume":"20","author":"SE Lipshultz","year":"2002","unstructured":"Lipshultz SE, Giantris AL, Lipsitz SR, et al.: Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002, 20:1677\u20131682.","journal-title":"J Clin Oncol"},{"issue":"6 Suppl 13","key":"146_CR33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.seminoncol.2004.08.006","volume":"31","author":"MS Ewer","year":"2004","unstructured":"Ewer MS, Martin FJ, Henderson C, et al.: Cardiac safety of liposomal anthracyclines. Semin Oncol 2004, 31(6 Suppl 13):161\u2013181.","journal-title":"Semin Oncol"},{"key":"146_CR34","first-page":"CD005006","volume":"5","author":"EC Dalen van","year":"2010","unstructured":"van Dalen EC, Michiels EM, Caron HN, Kremer LC: Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010, 5:CD005006.","journal-title":"Cochrane Database Syst Rev"},{"key":"146_CR35","first-page":"CD003917","volume":"1","author":"EC Dalen van","year":"2005","unstructured":"van Dalen EC, Caron HN, Dickinson HO, Kremer LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005, 1:CD003917.","journal-title":"Cochrane Database Syst Rev"},{"key":"146_CR36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mpo.10383","volume":"41","author":"L Kapusta","year":"2003","unstructured":"Kapusta L, Groot-Loonen J, Thijssen JM, et al.: Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy. Med Pediatr Oncol 2003, 41:426\u2013435.","journal-title":"Med Pediatr Oncol"},{"key":"146_CR37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euje.2005.04.009","volume":"7","author":"S Tassan-Mangina","year":"2006","unstructured":"Tassan-Mangina S, Codorean D, Metivier M, et al.: Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006, 7:141\u2013146.","journal-title":"Eur J Echocardiogr"},{"key":"146_CR38","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","volume":"28","author":"J Walker","year":"2010","unstructured":"Walker J, Bhullar N, Fallah-Rad N, et al.: Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010, 28:3429\u20133436.","journal-title":"J Clin Oncol"},{"key":"146_CR39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejheart.2004.03.009","volume":"7","author":"G Daugaard","year":"2005","unstructured":"Daugaard G, Lassen U, Bie P, et al.: Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005, 7:87\u201393.","journal-title":"Eur J Heart Fail"},{"key":"146_CR40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/0044011-200929020-00007","volume":"29","author":"T Cil","year":"2009","unstructured":"\u2022 Cil T, Kaplan AM, Altintas A, et al.: Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig 2009, 29:131\u2013137. In a prospective study, 33 patients with newly diagnosed breast cancer undergoing a total dose of doxorubicin of 240\u00a0mg\/m 2 were monitored for changes in ejection fraction and N-terminal pro-brain natriuretic peptide (NT-proBNP). A significant association was found between high NT-proBNP and reduced ejection fraction.","journal-title":"Clin Drug Investig"},{"key":"146_CR41","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM, et al.: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077\u20131084.","journal-title":"N Engl J Med"},{"key":"146_CR42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2004.06.022","volume":"22","author":"JH Silber","year":"2004","unstructured":"Silber JH, Cnaan A, Clark BJ, et al.: Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004, 22:820\u2013828.","journal-title":"J Clin Oncol"},{"key":"146_CR43","doi-asserted-by":"crossref","first-page":"26L","DOI":"10.1016\/S0002-9149(97)00846-1","volume":"80","author":"MR Bristow","year":"1997","unstructured":"Bristow MR: Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997, 80:26\u00a0L\u201340\u00a0L.","journal-title":"Am J Cardiol"},{"key":"146_CR44","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","volume":"48","author":"N Kalay","year":"2006","unstructured":"Kalay N, Basar E, Ozdogru I, et al.: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48:2258\u20132262.","journal-title":"J Am Coll Cardiol"},{"key":"146_CR45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00005344-200009000-00012","volume":"36","author":"T Tokudome","year":"2000","unstructured":"Tokudome T, Mizushige K, Noma T, et al.: Prevention of doxorubicin (Adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000, 36:361\u2013368.","journal-title":"J Cardiovasc Pharmacol"},{"key":"146_CR46","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","volume":"69","author":"A Riad","year":"2009","unstructured":"Riad A, Bien S, Westermann D, et al.: Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res 2009, 69:695\u2013699.","journal-title":"Cancer Res"},{"key":"146_CR47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1124\/jpet.107.125773","volume":"324","author":"KH Kim","year":"2008","unstructured":"Kim KH, Oudit GY, Backx PH: Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 2008, 324:160\u2013169.","journal-title":"J Pharmacol Exp Ther"},{"key":"146_CR48","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/dji087","volume":"97","author":"J Bohlius","year":"2005","unstructured":"Bohlius J, Langensiepen S, Schwarzer G, et al.: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005, 97:489\u2013498.","journal-title":"J Natl Cancer Inst"},{"key":"146_CR49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1034\/j.1600-0773.2001.d01-148.x","volume":"89","author":"MM Sayed-Ahmed","year":"2001","unstructured":"Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AM: Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol 2001, 89:140\u2013144.","journal-title":"Pharmacol Toxicol"},{"key":"146_CR50","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1158\/0008-5472.CAN-07-1344","volume":"67","author":"S Bien","year":"2007","unstructured":"Bien S, Riad A, Ritter CA, et al.: The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res 2007, 67:10428\u201310435.","journal-title":"Cancer Res"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-010-0146-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-010-0146-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-010-0146-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T15:19:04Z","timestamp":1636471144000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-010-0146-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,15]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1007\/s11906-010-0146-y","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,15]]}}}